Product InformationRegistration Status: Active
INLYTA TABLET 1MG is approved to be sold in Singapore with effective from 2013-11-03. It is marketed by PFIZER PTE LTD, with the registration number of SIN14321P.
This product contains Axitinib 1mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.
This product is manufactured by Pfizer Manufacturing Deutschland GmbH in GERMANY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Axitinib is marketed under the name Inlyta®, and if one previous systemic therapy for kidney cell cancer has failed, axitinib is indicated.
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Mechanism of Action
Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.
- After one 5 mg dose of axitinib, it takes about 2.5 to 4.1 hours to reach maximum plasma concentration.
- The volume of distribution is 160 L.
- Axitinib undergoes mainly hepatic metabolism. CYP3A4 and CYP3A5 are the main hepatic enzymes while CYP1A2, CYP2C19, and UGT1A1 enzymes are secondary.
The average clearance of axitinib is 38 L/h.
Some of the more serious toxic effects seen in patients taking axitinib include, but are not limited to, hypertension, thrombotic events, hemorrhage, and GI perforation.
axitinib | axitinibum | Axitinib |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.